Skip to content

Anesthetic effect of remimazolam with pre injection of alfentanil in gynaecological day surgery

Anesthetic effect of remimazolam with pre injection of alfentanil in gynaecological day surgery

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200066640
Enrollment
Unknown
Registered
2022-12-12
Start date
2022-12-15
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gynaecological day surgery

Interventions

control group:Giving 0 ug/kg alfentanil before giving remimazolam and 20 ug/kg alfentanil after falling asleep
Observation group 1:Giving 5ug/kg alfentanil before giving remimazolam and 15ug/kg alfentanil after sleeping
Observation group 2:Giving 10ug/kg alfentanil before giving remimazolam and 10ug/kg alfentanil after sleeping
Observation group 3:Giving 20ug/kg alfentanil before giving remimazolam and 0ug/kg alfentanil after sleeping

Sponsors

Weifang people's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: ? Day surgery patients who receive gynecological hysteroscopy or conization at a selected time; ? ASA ? - ? patients; ? Age 18-65; ? BMI 18.5~28

Exclusion criteria

Exclusion criteria: 1) Patients with psychosocial diseases and nervous system diseases 2) Patients who take antipsychotic drugs such as tranquilizer and antianxiety, and who drink or abuse drugs 3) Patients with language communication, vision or hearing impairment 4) Hypertension patients whose blood pressure was not controlled satisfactorily after antihypertensive drug treatment (sitting systolic blood pressure = 160mmHg, and/or diastolic blood pressure = 100mmHg in screening period) 5) SBP2, basic SpO2<92%); 8) Severe liver function damage; 9) Severe renal function damage; 10) Allergies to or contraindications to benzodiazepines, propofol, and their drug components; 11) Participated in clinical trials of Remazolam or other drugs as a subject in recent 3 months;

Design outcomes

Primary

MeasureTime frame
Induction dose of remimazolam;

Secondary

MeasureTime frame
Hemodynamic indexes;Adverse reactions during induction;AI anesthesia depth monitoring;Time of falling asleep, time of anesthesia and time of awakening;Postoperative adverse reactions;

Countries

China

Contacts

Public ContactJi Fanceng

Weifang people's Hospital

jifanceng@163.com13563698838

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026